JP2015508099A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508099A5
JP2015508099A5 JP2014558733A JP2014558733A JP2015508099A5 JP 2015508099 A5 JP2015508099 A5 JP 2015508099A5 JP 2014558733 A JP2014558733 A JP 2014558733A JP 2014558733 A JP2014558733 A JP 2014558733A JP 2015508099 A5 JP2015508099 A5 JP 2015508099A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
conr
conditions
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014558733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508099A (ja
JP6059260B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/070252 external-priority patent/WO2013126132A1/en
Publication of JP2015508099A publication Critical patent/JP2015508099A/ja
Publication of JP2015508099A5 publication Critical patent/JP2015508099A5/ja
Application granted granted Critical
Publication of JP6059260B2 publication Critical patent/JP6059260B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014558733A 2012-02-21 2012-12-18 環状ジアミノピリジン誘導体 Expired - Fee Related JP6059260B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601101P 2012-02-21 2012-02-21
US61/601,101 2012-02-21
PCT/US2012/070252 WO2013126132A1 (en) 2012-02-21 2012-12-18 Cyclic diaminopyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2015508099A JP2015508099A (ja) 2015-03-16
JP2015508099A5 true JP2015508099A5 (https=) 2016-12-08
JP6059260B2 JP6059260B2 (ja) 2017-01-11

Family

ID=47459190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558733A Expired - Fee Related JP6059260B2 (ja) 2012-02-21 2012-12-18 環状ジアミノピリジン誘導体

Country Status (10)

Country Link
US (1) US9073944B2 (https=)
EP (1) EP2817306B1 (https=)
JP (1) JP6059260B2 (https=)
CN (1) CN104254531B (https=)
AR (1) AR090103A1 (https=)
AU (1) AU2012370450B2 (https=)
CA (1) CA2865040C (https=)
ES (1) ES2552518T3 (https=)
IL (1) IL233986A (https=)
WO (1) WO2013126132A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
EP4225281A1 (en) * 2020-10-05 2023-08-16 Merck Patent GmbH Lmp7-selective inhibitors for the treatment of blood disorders and solid tumors
JP7556310B2 (ja) * 2021-02-26 2024-09-26 スズキ株式会社 電動車両
CA3212583A1 (en) 2021-03-27 2022-10-06 Daniel Gooding Compositions having improved bioavailability of therapeutics
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
EP4493151A2 (en) * 2022-03-14 2025-01-22 TRX Biosciences Limited Compositions having improved bioavailability of therapeutics and uses thereof
TW202404979A (zh) * 2022-07-18 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抑制並誘導egfr降解的大環類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
CN1863780A (zh) * 2002-08-14 2006-11-15 沃泰克斯药物股份有限公司 蛋白激酶抑制剂及其应用
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005012294A1 (en) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CA2631875A1 (en) * 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US7659280B2 (en) * 2006-02-17 2010-02-09 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
ATE540041T1 (de) * 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
KR20110073500A (ko) 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘

Similar Documents

Publication Publication Date Title
JP2015508099A5 (https=)
JP2015529657A5 (https=)
JP2015509512A5 (https=)
US9783513B2 (en) STAT3 inhibitors and their anticancer use
JP2015535831A5 (https=)
JP2015508086A5 (https=)
JP2014513729A5 (https=)
JP2015508085A5 (https=)
JP2014510774A5 (https=)
WO2019177975A1 (en) Antibiotics effective for gram-negative pathogens
RU2013148146A (ru) Производные адамантила
CN111727042A (zh) 微管蛋白抑制剂
US20210283153A1 (en) Carborane compounds and methods of use thereof
US20250281515A1 (en) Carborane compounds, carborane analogs, and methods of use thereof
JP2020002165A (ja) ジピコリルアミン誘導体及びそれらの薬学的使用
US9340501B2 (en) Marinopyrrole derivatives as anticancer agents
WO2023086365A1 (en) Compositions comprising amino lipid compounds and methods of making and use thereof
WO2023141538A1 (en) Compositions comprising lipid compounds and methods of making and use thereof
US8871983B2 (en) Lipid compounds for suppression of tumorigenesis
WO2019102054A1 (es) Análogos no glicosídicos de alfa-galactosilceramida como activadores de células nkt
US20160214941A1 (en) Compounds for lnhibition of Unregulated Cell Growth
US20250289837A1 (en) Mitochondriotropic heteroaryl benzamide potassium channel kv1.3 inhibitors
CA2914439A1 (en) Pharmaceutical compositions
US20250188098A1 (en) Carborane compounds and methods of use thereof
JP2023142282A (ja) 繊維化が生じる疾患の治療用医薬用組成物